期刊
BIOENGINEERED
卷 13, 期 1, 页码 128-139出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/21655979.2021.2009969
关键词
Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI); hyaluronic acid-gadolinium sesquioxide-nanoparticles (HA-Gd2o3-NPs); non-small cell lung cancer (NSCLC); clinic
This study aimed to explore the clinical efficacy and safety of EGFR-TKI targeted drugs combined with HA-Gd2O3-NPs in NSCLC. The results showed that the combined treatment significantly improved NSCLC survival rate under X-ray irradiation, and the total effective rate and one-year survival rate were significantly higher than the control group.
It was to explore the clinical efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) targeted drugs combined with hyaluronic acid-gadolinium sesquioxide-nanoparticles (HA-Gd2O3-NPs) in non-small cell lung cancer (NSCLC). In this study, 70 patients with stage IV EGFR mutant NSCLC diagnosed in the First Affiliated Hospital of Jinzhou Medical University were selected. They were randomly divided into the combined group (35 cases) and the control group (35 cases). HA-Gd2O3-NPs were prepared by hydrothermal polymerization, and combined with EGFR-TKI in the clinical treatment of NSCLC. The results showed that HA-Gd2O3-NPs were spherical with a uniform particle size of about 124 nm. The NSCLC survival rate of the combined group was 37.2 +/- 5.3% under 6 Gy X-ray irradiation, and that of the control group was 98.4 +/- 12.6% under 6 Gy X-ray irradiation. The total effective rate of the control group (20%) was significantly lower than that of the study group (42.86%) (P < 0.05). The one-year survival rate of the combined group (94%) was significantly higher than that of the control group (75%) (P < 0.05). The median progression-free survival (PFS) in the control group was 8 months, and that in the combined group was 12 months, with statistical difference (P < 0.05). EGFR-TKI targeted drugs combined with HA-Gd2O3-NPs can significantly improve the clinical efficacy of stage IV EGFR mutant NSCLC patients and benefit their survival.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据